[{"data":1,"prerenderedAt":9},["ShallowReactive",2],{"person-bio-sebastian-brunemeier":3},{"bio":4},[5,6,7,8],"Sebastian Brunemeier is a longevity-biotech investor and entrepreneur, co-founder and general partner of Healthspan Capital and co-founder and CEO of ImmuneAGE Pharma. He previously co-founded Cambrian Biopharma and studied the biology of ageing at the University of Oxford.","Before Healthspan Capital he was a principal at Apollo Health Ventures and co-founded Cambrian Biopharma and Samsara Therapeutics, having helped start four longevity companies in five years.","His interest in special jurisdictions is professional rather than ideological. Longevity medicine runs into a regulatory problem ordinary drug development does not have, because ageing is not classified as a disease, which leaves almost no approved route for trialling a therapy meant to prevent illness rather than treat it. Próspera is one of the few places where such trials are possible, and Brunemeier has taken part in the longevity biotech gatherings held there, including the Vitalia programme on Roatán.","He was a Clarendon Scholar at the University of Oxford, a Fulbright Fellow and a Skaggs-Oxford Scholar at Scripps Research, and holds a dual master’s degree in molecular neuroscience and biotech business management.",1788062494461]